OMASS TECHNOLOGIES
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
OMASS TECHNOLOGIES
Industry:
Life Science Pharmaceutical
Founded:
2016-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.omass.com
Total Employee:
11+
Status:
Active
Contact:
01865 548350
Total Funding:
118 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Maps API Google Cloud OpenResty
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Sentinel Oncology
Sentinel Oncology is a drug discovery company specialising in the delivery of candidate drugs to treat diseases.
XRnanotech
XRnanotech is a deep tech company that offers innovative nanostructured X-ray optics for high-tech applications.
Current Advisors List
Board_member
2022-04-27
Current Employees Featured
Ros Deegan CEO @ OMass Technologies
CEO
2019-04-01
Edward Hodgkin Chairman @ OMass Technologies
Chairman
2018-06-01
Ali Jazayeri Chief Scientific Officer @ OMass Technologies
Chief Scientific Officer
Jon Roffey VP, Head of Medicinal Chemistry @ OMass Technologies
VP, Head of Medicinal Chemistry
2022-01-01
Idlir Liko Co-Founder & CTO @ OMass Technologies
Co-Founder & CTO
Founder
Investors List
GV
GV investment in Series B - OMass Technologies
Northpond Ventures
Northpond Ventures investment in Series B - OMass Technologies
Syncona Partners LLP
Syncona Partners LLP investment in Series B - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Series B - OMass Technologies
Sanofi Ventures
Sanofi Ventures investment in Series B - OMass Technologies
Syncona Partners LLP
Syncona Partners LLP investment in Series A - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Series A - OMass Technologies
Syncona Partners LLP
Syncona Partners LLP investment in Series A - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Series A - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Seed Round - OMass Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-15 | OMass Therapeutics Appoints Dr Jon Roffey as Vice President, Head of Medicinal Chemistry |
Official Site Inspections
http://www.omass.com Semrush global rank: 3.88 M Semrush visits lastest month: 3.31 K
- Host name: 300480.cloudwaysapps.com
- IP address: 178.62.119.83
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
More informations about "OMass Technologies"
Omass
OMass Therapeutics is a biotechnology company developing novel small molecules for immunological and orphan diseases using proprietary biochemistry.See details»
Working Here - Omass
People at OMass are open and enjoy a highly collaborative environment. We expect transparency from each other and from the company, and value information-sharing to keep our collective …See details»
OMass Technologies - Org Chart, Teams, Culture & Jobs - The Org
View OMass Technologies' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
OMass Therapeutics - Crunchbase Company Profile & Funding
OMass Therapeutics closed its last funding round on May 15, 2023 from a Series B round. Who are OMass Therapeutics 's competitors? Alternatives and possible competitors to OMass …See details»
OMass Therapeutics Announces New Phase of Growth …
Apr 19, 2023 OMass Therapeutics : Consilium Strategic Communications : Rosamond Deegan, Chief Executive Officer Phone: +44 (0) 1235 527589 Email: ros.deegan@omass.com Sue Charles/Stella Lempidaki/Kumail WaljeeSee details»
About OMass Therapeutics - pharmiweb.jobs
Jan 18, 2024 OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs. …See details»
OMass Therapeutics Expands Leadership Team with Two New …
Feb 8, 2023 Oxford, United Kingdom – 02 August 2023 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines against highly validated target …See details»
OMass Therapeutics: Creating groundbreaking …
In 2022, OMass was awarded a $100 million investment from an international syndicate, to progress its drug pipeline of small molecule therapeutics, using its proprietary OdyssION TM drug discovery platform. To help their team achieve …See details»
OMass Therapeutics Announces New Phase of Growth with Move …
Apr 19, 2023 Oxford, United Kingdom – 19 April 2023 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines against highly validated target …See details»
About – Overview – Omass
At OMass Therapeutics, we are identifying new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry. We distil biology to its …See details»
OMass - Begbroke Science Park
Using this technology allows OMass to interrogate not just the target but how it interacts with its native ecosystem, separate from the confounding complexity of the cell. The company was …See details»
PRESS RELEASE OMass Therapeutics Expands Development Team …
OMass Therapeutics ICR Consilium Rosamond Deegan, Chief Executive Officer Phone: +44 (0) 1235 527589 Email: ros.deegan@omass.com Sue Charles / Suki Virji / Kumail Waljee Phone: …See details»
OMass Therapeutics: New technology for drug ... - University of …
OMass’ work is based on novel mass spectrometry approaches, developed in Professor Dame Carol Robinson’s Laboratory, which enable the study of proteins in the cell membrane (the …See details»
OMass Therapeutics Ltd. (OMass Therapeutics Ltd.) - 药物管线_专 …
了解OMass Therapeutics Ltd. (OMass Therapeutics Ltd.)公司的药物管线，治疗领域，技术平台，以及它的25篇新闻和10篇文献，疾病领域:免疫系统疾病，感染，内分泌与代谢疾病，技术 …See details»
OMass Therapeutics Announces New Phase of Growth with Move …
Apr 19, 2023 OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs. …See details»
OMass Therapeutics Expands Development Team with Key …
Jan 10, 2024 OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins …See details»
In The News - Omass
Mar 11, 2024 Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well as canniness): …See details»
OMass Unveils Rich Drug Discovery Pipeline Targeting
Nov 4, 2021 OMass Therapeutics : Consilium Strategic Communications : Rosamond Deegan, Chief Executive Officer Phone: +44 (0) 1235 527589 Email: ros.deegan@omass.com Sue …See details»
Organized Medical Staff | American Medical Association
Apr 16, 2025 Organization; Board of Trustees; House of Delegates. House of Delegates; HOD Organization; AMA Policies; Annual Meeting; Interim Meeting; AMA Elections; SSS, Section …See details»
OMass Therapeutics Raises $100 Million in Series B Financing to ...
Email: ros.deegan@omass.com Sue Charles / Chris Gardner / Kumail Waljee Phone: +44 (0)20 3709 5700 Email: omass@consilium-comms.com About OMass Therapeutics OMass …See details»